Inve India ▾

Glenmark Pharmaceuticals share price & results

Glenmark Pharmaceuticals Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Global pharma company with branded generics, specialty and innovative oncology/dermatology/respiratory portfolios across 80+ countries.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue2,435 ₹ crore+1.7% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin25.0 %−5.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit736 ₹ crore+123.0% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity32.23 %+7.8 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin12.30 %+24.1 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)32.94 %+14.7 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

7 of 8 judged targets kept · 18 open · verdicts reflect calls analysed to Q1 FY27.

Glenmark Pharmaceuticals Limited management guidance track record on Inve: 26 targets tracked across analysed earnings calls (7 achieved, 1 missed, 18 open).

TargetOriginal wordingSaidLatest callVerdict
RYALTRIS Global Sales$80 million for FY25
Call transcript, Q3 FY25 · 17 Feb 2025		Q3 FY25Q1 FY27:This promise for FY25/FY26 targets remains achieved. A separate promise tracks long-term growth.
Call transcript, Q1 FY27 · 3 Aug 2026		Achieved
Total CapexAround INR 900 crores for FY27 onwards
Call transcript, Q4 FY26 · 1 Jun 2026		Q4 FY26Q1 FY27:No specific update on capex spend provided in the Q1 FY27 call or materials.
Call transcript, Q1 FY27 · 3 Aug 2026		Ghosted
EBITDA Margin19% to 20% for FY26
Call transcript, Q4 FY25 · 26 May 2025		Q4 FY25Q1 FY27:The final verdict for the FY26 journey was a downward revision of future expectations, even though the interim target was met.
Call transcript, Q1 FY27 · 3 Aug 2026		Revised Down

Source: Inve Guidance Tracker for Glenmark Pharmaceuticals Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

1 of Glenmark Pharmaceuticals Limited's 26 targets was missed. See which ones, and which are quietly gone. The 3 above are the free sample; 23 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹2,225.8 +2.73% · +₹59.2

Last close 26 Oct 2026 · NSE · INR · Source: Inve

Performance +22.4% 1Y

₹1.8k₹2.0k₹2.2k₹2.4kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 17 Nov 2025Q3 FY26 — 2 Feb 2026Q4 FY26 — 1 Jun 2026Q1 FY27 — 3 Aug 2026

1Y: ₹1,818.8 on 24 Oct 2025 → ₹2,225.8. High ₹2,515 (28 Aug 2026), low ₹1,810.4 (6 Nov 2025).

Previous close
₹2,166.6
Market cap
₹63.9k Cr
52-week range
₹1,810.4 – ₹2,515
One year
+22.79%
Price to earnings (TTM to Jun 2026)
20.47×
Return on equity (TTM to Jun 2026)
32.23%

Overview

Symbol
NSE:GLENMARK
Exchange
NSE
Currency
INR

What Glenmark Pharmaceuticals Limited does

Based on the company's own presentations, annual report and earnings calls.

Glenmark Pharmaceuticals develops, manufactures and markets branded generics, specialty and OTC medicines, with deep therapeutic focus on Oncology, Dermatology and Respiratory. It earns revenue from branded and generic formulation sales across India, the US, Europe, Latin America, APAC, Middle East and Africa, supplemented by out-licensing and milestone payments from its innovative pipeline. Its biotech arm, Ichnos Glenmark Innovation (IGI), discovers multispecific antibodies via the proprietary BEAT platform and partners globally (e.g. ISB 2001 licensed to AbbVie) to monetize novel oncology and immunology assets. Manufacturing spans API and formulation sites feeding both regulated and emerging markets.

Segments

  • India Formulations
  • North America
  • Europe
  • Emerging Markets
  • Ichnos Glenmark Innovation (IGI)
Manufacturing sites globally
11
R&D centres
4
Global employee base
~17,000
Countries with commercial presence
80+
Key global therapeutic areas
3 (Oncology, Dermatology, Respiratory)
Out-licensing deals executed since 2004
10
Founded 1977Headquarters Mumbai, IndiaEmployees 17,000 (April 2026) Company website

How the price took the results

close before → close after

Q1 FY27
−0.2%
3 Aug
Q4 FY26
−3.2%
1 Jun
Q3 FY26
−1.0%
2 Feb
Q2 FY26
−1.4%
17 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Glenmark Pharmaceuticals Limited

Free account: one company. Everything above stays public.

Write why you follow Glenmark Pharmaceuticals Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Glenmark Pharmaceuticals Limited

Guides on how to read this kind of business and the numbers that matter.